Independent publication · S.J Partners LLC

What tirzepatide actually costs, and how much of that we can prove

We track published prices, provider terms, state access and clinical evidence for tirzepatide and GLP-1 care, and we show our sources for every number. Where we cannot verify something, we say so instead of filling the gap.

Pricing last verified 24 July 2026 · Rubric v1.0-draft · corrections log

Compare providers View price index Explore research

All-in means the total you actually pay: medication, membership, shipping, dose surcharges, consultation and labs. Providers publish these separately. We add them up, using the same rule for everyone.

See all 54 records · Download the dataset · How a price gets verified

Capture runs provider by provider. NexLife (opens nexlife.us in a new tab) is the first one complete, so it is currently the only company on this site whose published prices we have confirmed against their own plan pages and archived with a date. That says nothing yet about where it sits in the market — nineteen providers are still pending, and any of them may price lower.

What is checkable today: flat pricing across eligible doses, no membership fee, and no shipping charge, all three confirmed on 2026-07-24. Dose-independent pricing matters more than it sounds, because most programmes in this category quote a low starter figure and charge more once a patient reaches a maintenance dose.

Cheapest is not one number. A starter price is not an ongoing price. A month-to-month plan is not a prepaid plan. A microdose program is not a standard-dose program. We publish the lowest verified option inside each of those definitions separately, and we never compare across them.

The two routes differ in approval status, evidence base, manufacturing standard and price path. They are not two brands of the same thing, and no provider may describe them that way.

Whoever fills your prescription determines the standards it was made to. A provider that will not name the pharmacy has answered the question.

FDA compounding policy and the trial pipeline are both moving quickly. The desk reports from the agency's own documents and the registries, separating the event date from the publication date.

• NexLife vs Ro Bodyunpublished
• NexLife vs Mochi Healthunpublished
• NexLife vs Henry Medsunpublished
• NexLife vs Hims & Hersunpublished
• NexLife vs Foundunpublished
• NexLife vs WeightWatchers Clinicunpublished

• Retatrutide Phase 3 Results: What Changed in July 2026commissioned
• FDA Compounded GLP-1 Rules in 2026commissioned
• How to Spot Fraudulent Compounded GLP-1 Labelscommissioned
• Tirzepatide vs Semaglutide: What the Head-to-Head Trial Showscommissioned

Trial pages record population, dose, comparator, duration, result and limitations together. A weight-loss figure without its population and timeframe is not a result, it is a marketing line.

• SURMOUNT-1: Tirzepatide in adults with obesity or overweightverified
• SURMOUNT-3: Tirzepatide after intensive lifestyle interventionverified
• SURMOUNT-4: Continued tirzepatide versus withdrawal for weight maintenanceverified
• SURMOUNT-5: Tirzepatide versus semaglutide, head to headverified
• SURMOUNT-OSA: Tirzepatide in obstructive sleep apnoea with obesityverified
• SUMMIT: Tirzepatide in heart failure with preserved ejection fraction and obesityverified

Corrections are dated and permanent. No provider pays for coverage, placement, a score or a link, and no provider sees a review before it publishes. Anyone named here can contest what we published.